A phase II study investigating neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer: Final analysis

Simple item page
dc.conference.dateNOV 20-22, 2020
dc.conference.titleESMO Asia Virtual Congress
dc.contributor.authorSzabados, B. E.
dc.contributor.authorRodriguez-Vida, A.
dc.contributor.authorDuran, I.
dc.contributor.authorCrabb, S. J.
dc.contributor.authorvan-der-Heijden, M. S.
dc.contributor.authorPous, A. Font
dc.contributor.authorGravis, G.
dc.contributor.authorHerranz, U. Anido
dc.contributor.authorProtheroe, A.
dc.contributor.authorRavaud, A.
dc.contributor.authorMaillet, D.
dc.contributor.authorMendez, M. J.
dc.contributor.authorSuarez, C.
dc.contributor.authorLinch, M.
dc.contributor.authorPrendergast, A.
dc.contributor.authorTyson, C.
dc.contributor.authorMousa, K.
dc.contributor.authorCastellano, D.
dc.contributor.authorPowles, T. B.
dc.contributor.authoraffiliation[Szabados, B. E.] Barts Canc Inst, Dept Med Oncol, London, England
dc.contributor.authoraffiliation[Rodriguez-Vida, A.] Hosp del Mar, Dept Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Duran, I.] Hosp Univ Virgen del Rocio, CSIC, Seville, Spain
dc.contributor.authoraffiliation[Duran, I.] Univ Seville, Inst Biomed Sevilla, Seville, Spain
dc.contributor.authoraffiliation[Crabb, S. J.] Univ Southampton, Southampton Expt Canc Med Ctr, Southampton, Hants, England
dc.contributor.authoraffiliation[van der Heijden, M. S.] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands
dc.contributor.authoraffiliation[Pous, A. Font] Hosp Badalona Germans Trias & Pujol, Badalona Appl Res Grp Oncol B ARGO IGTP, Catalan Inst Oncol, Badalona, Spain
dc.contributor.authoraffiliation[Gravis, G.] Aix Marseille Univ, Med Oncol Dept, Nstitut Paoli Calmettes, Inserm,CNRS,CRCM, Marseille, France
dc.contributor.authoraffiliation[Herranz, U. Anido] Hosp Clin Univ Santiago, Med Oncol, Bordeaux, France
dc.contributor.authoraffiliation[Protheroe, A.] Churchill Hosp, Oncol, Oxford, England
dc.contributor.authoraffiliation[Ravaud, A.] Hop St Andre, Oncol, Bordeaux, France
dc.contributor.authoraffiliation[Maillet, D.] Hosp Lyon Sud, Oncol, Lyon, France
dc.contributor.authoraffiliation[Mendez, M. J.] Reina Sofia Univ Hosp, Oncol, Cordoba, Spain
dc.contributor.authoraffiliation[Suarez, C.] Vall dHebron Inst Oncol, Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Linch, M.] UCL, Inst Canc, Oncol, London, England
dc.contributor.authoraffiliation[Prendergast, A.] Barts Expt Canc Med Ctr, Barts Canc Inst, London, England
dc.contributor.authoraffiliation[Mousa, K.] Barts Expt Canc Med Ctr, Barts Canc Inst, London, England
dc.contributor.authoraffiliation[Tyson, C.] Barts Expt Canc Med Ctr, Barts Canc Inst, London, England
dc.contributor.authoraffiliation[Castellano, D.] Hosp 12 Octubre, Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Powles, T. B.] St Bartholomews Hosp, Oncol, London, England
dc.contributor.funderRoche
dc.contributor.funderRoche
dc.date.accessioned2025-01-07T13:24:17Z
dc.date.available2025-01-07T13:24:17Z
dc.date.issued2020-11-01
dc.description.abstractBackground. ABACUS is a phase II single-arm study that evaluated the safety and efficacy of neoadjuvant atezolizumab in patients with muscle-invasive bladder cancer (MIBC) awaiting radical cystectomy (RC). Methods. This single arm, phase II study investigated two cycles of atezolizumab (1200mg given every 3 weeks) prior to RC in MIBC(T2-4aN0M0) (NCT02662309). The study included patients who were ineligible or refused neoadjuvant cisplatin-based chemotherapy and had transitional cell histology. Pathological complete response (pCR) was the primary endpoint. Adverse events (AEs) and surgical complications were assessed using CTCAE v4.03 and the Clavien-Dindo classification.
dc.identifier.citationSzabados, B. E. Rodriguez-Vida, A. Duran, I., Crabb, S. J., van-der-Heijden, M. S., Pous, A. Font et al. A phase II study investigating neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer: Final analysis. Ann. oncol.2020; (31);S1319
dc.identifier.doi10.1016/j.annonc.2020.10.211
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753420427024/pdf
dc.identifier.urihttps://hdl.handle.net/10668/25477
dc.identifier.wosID600988900203
dc.issue.number6
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Reina Sofía
dc.organizationInstituto de Investigación Biomédica de Sevilla (IBIS)
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.page.numberS1319
dc.provenanceRealizada la curación de contenido 06/03/2025
dc.publisherElsevier
dc.relation.publisherversionhttps://www.annalsofoncology.org/article/S0923-7534(20)42702-4/fulltext
dc.rights.accessRights Restricted Access
dc.subjectCisplatin
dc.subjectatezolizumab
dc.subjectUrinary Bladder Neoplasms
dc.subjectMuscles
dc.subject.decsPacientes
dc.subject.decsBrazo
dc.subject.decsCisplatino
dc.subject.decsCistectomía
dc.subject.decsHistología
dc.subject.decsNeoplasias de la vejiga urinaria
dc.subject.decsCélulas
dc.subject.decsQuimioterapia
dc.subject.decsReacción en cadena de la Polimerasa
dc.subject.meshHumans
dc.subject.meshCystectomy
dc.subject.meshNeoadjuvant Therapy
dc.titleA phase II study investigating neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer: Final analysis
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number31
dc.wostypeMeeting Abstract

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
RISalud_Accesorestringido.pdf
Size:
93.39 KB
Format:
Adobe Portable Document Format
Download

Collections

SAS - Hospital Universitario Virgen del Rocío
Instituto de Investigación Biomédica de Sevilla (IBIS)
SAS - Hospital Universitario Reina Sofía

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía